Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
S. Eftekhari, Hamed Montazeri, Parastoo Tarighi
Topics & Concepts
LNCaPLiraglutideDocetaxelProstate cancerAgonistMedicineInternal medicineCancer researchEndocrinologyGlucagon-like peptide 1 receptorProstateReceptorCancerType 2 diabetesDiabetes mellitusProstate Cancer Treatment and ResearchDiabetes Treatment and ManagementMetabolism, Diabetes, and Cancer